The majority of people with myasthenia gravis (MG) who contracted Coronavirus disease 2019 (COVID-19) in the study recovered and the use of immunosuppressive therapies and corticosteroids were not risk factors for severe COVID-19. People who had a high Myasthenia Gravis Foundation of America (MGFA) class prior to infection had an increased risk for severe COVID-19.
Why this matters
People with MG who contract COVID-19 may be particularly vulnerable to poor clinical outcomes due to the use of immunosuppressive treatments for MG management. To date, evidence to support or halt the use of immunosuppressive therapies in people with MG during the COVID-19 pandemic is lacking.